China Deal-Making Now: New Opportunities and Barriers

Deloitte reports a cooling down effect in biopharma cross-border transactions in 2019 due political and trade tensions. When comparing against recent years, deal counts have decreased and deal values are remaining flat, with over 83% of deals under $100m. While the current pandemic has also added to this trend, further disrupting partnership opportunities with Chinese companies, it has also prompted other forms of biopharma collaborations. Join China deal-making experts from pharma, biotech and venture as they discuss what factors are being considered in evaluating current partnership opportunities.